Compare WPRT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | ATNM |
|---|---|---|
| Founded | 1995 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 31.7M |
| IPO Year | 2006 | 2013 |
| Metric | WPRT | ATNM |
|---|---|---|
| Price | $2.09 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.38 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 841.5K | 120.9K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.74 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $1.54 | $0.94 |
| 52 Week High | $4.14 | $1.89 |
| Indicator | WPRT | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 38.79 |
| Support Level | $1.75 | N/A |
| Resistance Level | $2.15 | $1.27 |
| Average True Range (ATR) | 0.21 | 0.05 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 40.74 | 15.38 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three reportable segments: High-Pressure Controls, Heavy-Duty OEM, and Cespira. It derives maximum revenue from Heavy-Duty OEM segment. Heavy-Duty OEM segment's products include HPDI related fuel system solutions and components. Geographically, the company operates in Europe, America and Asia, of which it generates maximum revenue from Europe. It also develops and supplies advanced LPG, CNG, LNG and H2 systems and components for OEM (original equipment manufacturer) D-OEM (delayed oem) and After Market (retrofit market) world-wide.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.